This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n21http://localhost/temp/predkladatel/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n5http://linked.opendata.cz/resource/domain/vavai/projekt/
n14http://linked.opendata.cz/resource/domain/vavai/subjekt/
n8http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11130%2F13%3A10196669%21RIV14-MZ0-11130___/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n16http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11130%2F13%3A10196669%21RIV14-MZ0-11130___
rdf:type
skos:Concept n13:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1016/j.ygyno.2012.10.002
dcterms:description
Objective. The endpoint of this prospective study is to evaluate response rate, survival and toxicity of high-dose density neoadjuvant chemotherapy (NAC) in bulky IB cervical cancer. Material and methods. Between January 1998 and December 2009, 154 women were enrolled into study. Three patients were withdrawn. Of the 151 women, 119 had stage IB2 cervical cancer (78.8%) and 32 had stage IB1 cancer (21.2%) infiltrating the whole cervical stroma. Women received 3-4 cycle cisplatin-75 mg/m(2) and ifosfamide-2 g/m(2) in cases of squamous-cell cancer or cisplatin-75 mg/m(2) and doxorubicin-35 mg/m(2) in adenocarcinoma every 10 days and then underwent radical hysterectomy type III. Patients who had non-resectable disease underwent chemoradiotherapy. Results. The overall response rate (reduction of tumor volume more than 50%) was 78.8%. Reduction of tumor volume less than 50% was seen in 15.2%. Tumor progression during chemotherapy occurred in nine patients (6.0%). There were positive lymph-nodes in 26 patients (18.3%) of the 142 that underwent surgery. 38 women underwent adjuvant radiotherapy (26.7%). There were 26 recurrences (17.2%). After surgery 20 women recurred from 142 (14.1%) and after primary radiotherapy 6 from 9 women recurred (66.7%). 25 of 151 women died from disease (16.5%). At the time of the study, surgery was performed in 118 women 5 or more years ago, 19 of them died of disease. Five-year specific survival is 83.6%. Grade 3-4 -neutropenia was found in only 7.3% of the women, and grade 3-4 thrombocytopenia were found in 1.3%. Conclusion. High-dose density NAC appears to be feasible in the treatment IB bulky cervical cancer and toxicity is acceptable. Adjuvant radiotherapy was used only in 26.7%. Objective. The endpoint of this prospective study is to evaluate response rate, survival and toxicity of high-dose density neoadjuvant chemotherapy (NAC) in bulky IB cervical cancer. Material and methods. Between January 1998 and December 2009, 154 women were enrolled into study. Three patients were withdrawn. Of the 151 women, 119 had stage IB2 cervical cancer (78.8%) and 32 had stage IB1 cancer (21.2%) infiltrating the whole cervical stroma. Women received 3-4 cycle cisplatin-75 mg/m(2) and ifosfamide-2 g/m(2) in cases of squamous-cell cancer or cisplatin-75 mg/m(2) and doxorubicin-35 mg/m(2) in adenocarcinoma every 10 days and then underwent radical hysterectomy type III. Patients who had non-resectable disease underwent chemoradiotherapy. Results. The overall response rate (reduction of tumor volume more than 50%) was 78.8%. Reduction of tumor volume less than 50% was seen in 15.2%. Tumor progression during chemotherapy occurred in nine patients (6.0%). There were positive lymph-nodes in 26 patients (18.3%) of the 142 that underwent surgery. 38 women underwent adjuvant radiotherapy (26.7%). There were 26 recurrences (17.2%). After surgery 20 women recurred from 142 (14.1%) and after primary radiotherapy 6 from 9 women recurred (66.7%). 25 of 151 women died from disease (16.5%). At the time of the study, surgery was performed in 118 women 5 or more years ago, 19 of them died of disease. Five-year specific survival is 83.6%. Grade 3-4 -neutropenia was found in only 7.3% of the women, and grade 3-4 thrombocytopenia were found in 1.3%. Conclusion. High-dose density NAC appears to be feasible in the treatment IB bulky cervical cancer and toxicity is acceptable. Adjuvant radiotherapy was used only in 26.7%.
dcterms:title
High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer
skos:prefLabel
High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer
skos:notation
RIV/00216208:11130/13:10196669!RIV14-MZ0-11130___
n13:predkladatel
n14:orjk%3A11130
n3:aktivita
n4:I n4:P
n3:aktivity
I, P(NT13166)
n3:cisloPeriodika
1
n3:dodaniDat
n11:2014
n3:domaciTvurceVysledku
n6:1850660 n6:2066408 n6:8504571 n6:7462395 n6:4745531 n6:7298471 n6:9967567 n6:5371236
n3:druhVysledku
n18:J
n3:duvernostUdaju
n10:S
n3:entitaPredkladatele
n8:predkladatel
n3:idSjednocenehoVysledku
77383
n3:idVysledku
RIV/00216208:11130/13:10196669
n3:jazykVysledku
n19:eng
n3:klicovaSlova
Quality of life; Tumor volumometry; High-dose density neoadjuvant chemotherapy; Cervical cancer
n3:klicoveSlovo
n9:Quality%20of%20life n9:High-dose%20density%20neoadjuvant%20chemotherapy n9:Cervical%20cancer n9:Tumor%20volumometry
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[14D18E5760FF]
n3:nazevZdroje
Gynecologic Oncology
n3:obor
n17:FK
n3:pocetDomacichTvurcuVysledku
8
n3:pocetTvurcuVysledku
8
n3:projekt
n5:NT13166
n3:rokUplatneniVysledku
n11:2013
n3:svazekPeriodika
128
n3:tvurceVysledku
Škapa, Petr Halaška, Michael Komár, Matej Pluta, Marek Lisý, Jiří Robová, Helena Strnad, Pavel Rob, Lukáš
n3:wos
000313386900010
s:issn
0090-8258
s:numberOfPages
5
n16:doi
10.1016/j.ygyno.2012.10.002
n21:organizacniJednotka
11130